As of February 2025, Xiidra (lifitegrast ophthalmic solution 5%) maintains leading insurance coverage among branded dry eye prescriptions in the U.S. According to MMIT data, up to 94% of commercially insured patients and 70% under Medicare Part D have coverage eligibility. These figures align with Xiidra’s positioning as a cost-accessible option for a broad patient base. Patient-assistance mechanisms, including the Xiidra® iinsider™ savings card program, enable eligible commercially insured patients to pay as little as $0 per refill, with potential annual savings up to $1,440. Without insurance, retail prices range between $500–700 for a 30-day supply, which can pose affordability barriers. The AAO Preferred Practice Pattern lists Xiidra alongside therapeutically equivalent alternatives like Miebo and cyclosporine formulations as a Step 2 treatment for DED, though no head-to-head trials define superiority. With upcoming generic risk (patent expiry by 2026–2028), Xiidra’s coverage strength and copay support remain key determinants of ongoing market share retention.

Citation:
https://www.xiidra.com/xiidra-cost

Implications:
Xiidra’s extensive payer coverage and robust assistance programs sustain its competitive advantage in the 2025 DED marketplace. As generic entry risk increases, maintaining access and affordability will be critical to preserving its clinician adoption and patient retention, especially in value-sensitive settings.